NovMetaHealth

For Your Healthy Life, NovMetaHealth

NovCK

Pipeline
NovCK
Program Target
Cytokine Release Syndrome
Development Stage
Research
NovMetaHealth researches and develops NovCK, a new substance-based cytokine inhibitor.

NovMetaHealth is researching NovCK, a new substance-based cytokine inhibitor and it is expected to be able to treat Cytokine Release Syndrome. Which is caused by various infectious diseases including COVID-19.

N20 effect: poly I:C medication-induced BMBM activation model
N20 reducing cytokine release

NovCK Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Preclinical

Clinical phase 1/2a

02

Patent Application and Registration Status
Patents IP Protection
Cytokine inhibition patent (US)
Application
2020
Patent expiration (expected) year
(2040)